Barclays Maintains Equal-Weight on Biogen, Lowers Price Target to $180
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould maintains an Equal-Weight rating on Biogen and lowers the price target from $190 to $180.
October 31, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Barclays has maintained its Equal-Weight rating on Biogen but has lowered the price target from $190 to $180, indicating a slightly less optimistic outlook.
The lowering of the price target by Barclays suggests a less optimistic view on Biogen's stock performance, which could lead to a negative short-term impact on the stock price. The Equal-Weight rating indicates a neutral stance, but the reduced price target may influence investor sentiment negatively.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100